title: Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation.
abstract: BACKGROUND
  Although human herpesvirus 6 (HHV-6) is known to reactivate during hematopoietic stem cell transplantation (HSCT), the clinical significance of this finding is controversial.
  
  
  METHODS
  We used a quantitative PCR test for HHV-6 to assay plasma samples prospectively collected from a cohort of 110 allogeneic HSCT recipients to evaluate the clinical effects of HHV-6 infection. A retrospective review of medical records was performed to determine clinical end points.
  
  
  RESULTS
  HHV-6 reactivation occurred in 52 (47%) of the 110 subjects. Factors that increased the risk of subsequent HHV-6 reactivation were hematologic malignancy that occurred at a time other than the first remission (adjusted P = .002), a mismatch in the sexes of donor and recipient (adjusted P=.05), younger age (adjusted P = .01), and the receipt of glucocorticoids (adjusted P = .06). HHV-6 reactivation was associated with subsequent all-cause mortality (adjusted hazard ration [HR], 2.9; 95% confidence interval [CI], 1.1-7.5), grade 3-4 graft-versus-host disease (GVHD) (adjusted HR, 4.9; 95% CI, 1.5-16), a lower probability of monocyte engraftment (adjusted HR, 0.42; 95% CI; 0.22-0.80), a lower probability of platelet engraftment (adjusted HR, 0.47; 95% CI, 0.21-1.1; P = .05) and a higher platelet transfusion requirement (adjusted P = .02). A higher level of HHV-6 DNA was associated with subsequent central nervous system (CNS) dysfunction (HR, 21; 95% CI, 1.8-249).
  
  
  CONCLUSIONS
  HHV-6 reactivation is common after allogeneic HSCT and is associated with subsequent delayed monocyte and platelet engraftment, increased platelet transfusion requirements, all-cause mortality, grade 3-4 GVHD, and CNS dysfunction.
authors.affiliation: Department of Pediatrics, University of Washington, Seattle, Washington, USA. zerr@u.washington.edu
authors.forename: Danielle M
authors.initials: DM
authors.lastname: Zerr
authors.forename: Lawrence
authors.initials: L
authors.lastname: Corey
authors.forename: Hyung W
authors.initials: HW
authors.lastname: Kim
authors.forename: Meei-Li
authors.initials: ML
authors.lastname: Huang
authors.forename: Long
authors.initials: L
authors.lastname: Nguy
authors.forename: Michael
authors.initials: M
authors.lastname: Boeckh
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015331:Cohort Studies; D004279:DNA, Viral / Q000097:blood; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D015654:Herpesvirus 6, Human / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017713:Platelet Transfusion; D012307:Risk Factors; D019349:Roseolovirus Infections / Q000209:etiology / Q000821:virology*; D013997:Time Factors; D014775:Virus Activation
chemical_list: D004279:DNA, Viral